Oppenheimer Discusses Compelling Data from ArQuel (ARQL) at ASCO
Tweet
Share
E-mailGet Alerts ARQL Hot Sheet
Price: $20.00 --0%
Rating Summary:
7 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
7 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Oppenheimer commented on ArQule (NASDAQ: ARQL) following this weekend's ASCO noting compelling tivantinib ph.II 2nd-line HCC results.
The firm comments, "The ph.II trial met the primary PFS endpoint, and tivantinib demonstrated significant TTP/PFS/OS benefit (HR=0.43/0.45/0.38) vs. placebo in the high c-MET expression subpopulation (~50% of pts), which, importantly, was a prespecified analysis. Notably, grade 3/4 neutropenia was low (6%) at the 240mg, go-forward dose. Based on these results, we see a clear path to ph.III success, but ARQL currently reflects no value for this opportunity."
The firm maintained their Outperform rating and price target of $11.00
For an analyst ratings summary and ratings history on ArQule click here. For more ratings news on ArQule click here.
Shares of ArQule closed at $5.53 yesterday.
The firm comments, "The ph.II trial met the primary PFS endpoint, and tivantinib demonstrated significant TTP/PFS/OS benefit (HR=0.43/0.45/0.38) vs. placebo in the high c-MET expression subpopulation (~50% of pts), which, importantly, was a prespecified analysis. Notably, grade 3/4 neutropenia was low (6%) at the 240mg, go-forward dose. Based on these results, we see a clear path to ph.III success, but ARQL currently reflects no value for this opportunity."
The firm maintained their Outperform rating and price target of $11.00
For an analyst ratings summary and ratings history on ArQule click here. For more ratings news on ArQule click here.
Shares of ArQule closed at $5.53 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Upgrades CAE Inc. (CAE:CN) (CAE) to Outperform
- Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy
- Jefferies Starts Freenome Inc. (FRNM) at Buy
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
